Ian A. Cliffe

3.1k total citations · 1 hit paper
43 papers, 2.5k citations indexed

About

Ian A. Cliffe is a scholar working on Molecular Biology, Organic Chemistry and Cellular and Molecular Neuroscience. According to data from OpenAlex, Ian A. Cliffe has authored 43 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 18 papers in Organic Chemistry and 14 papers in Cellular and Molecular Neuroscience. Recurrent topics in Ian A. Cliffe's work include Neurotransmitter Receptor Influence on Behavior (11 papers), Receptor Mechanisms and Signaling (11 papers) and Pharmacological Receptor Mechanisms and Effects (7 papers). Ian A. Cliffe is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (11 papers), Receptor Mechanisms and Signaling (11 papers) and Pharmacological Receptor Mechanisms and Effects (7 papers). Ian A. Cliffe collaborates with scholars based in United Kingdom, India and Norway. Ian A. Cliffe's co-authors include Allan Fletcher, David J. Bill, Deborah E. Jones, Colin T. Dourish, Victor W. Pike, Julie A. McCarron, A Fletcher, Howard L. Mansell, Susan P. Hume and Christopher J. Bench and has published in prestigious journals such as Neurology, Brain Research and Journal of Medicinal Chemistry.

In The Last Decade

Ian A. Cliffe

43 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635

1995 550 citations Ian A. Cliffe, David J. Bill et al. European Journal of Pharmacology profile →

Peers

Countries citing papers authored by Ian A. Cliffe

Since Specialization

Citations

This map shows the geographic impact of Ian A. Cliffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian A. Cliffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian A. Cliffe more than expected).

Fields of papers citing papers by Ian A. Cliffe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian A. Cliffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian A. Cliffe. The network helps show where Ian A. Cliffe may publish in the future.

Co-authorship network of co-authors of Ian A. Cliffe

This figure shows the co-authorship network connecting the top 25 collaborators of Ian A. Cliffe. A scholar is included among the top collaborators of Ian A. Cliffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian A. Cliffe. Ian A. Cliffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy 2013 ·European Journal of Pharmacology ·Ruchi Tandon, (unknown), (unknown), (unknown), Ankur Kumar, (unknown), (unknown), Manish Diwan, (unknown), R. Venkataramanan, (unknown), Biswajit Das, Sunanda G. Dastidar, Ian A. Cliffe, Abhijit Ray, Pradip K. Bhatnagar	8
2	Synthesis and evaluation of 4,5-dihydro-5-methylisoxazolin-5-carboxamide derivatives as VLA-4 antagonists 2012 ·Bioorganic & Medicinal Chemistry Letters ·Ajay Soni, Abdul Rehman, (unknown), Sunanda G. Dastidar, Mohammad Sarwar Alam, Abhijit Ray, (unknown), Vanya Shah, Venkata P. Palle, Ian A. Cliffe, (unknown)	10
3	Synthesis and in vitro activity of novel 1,2,4-triazolo[4,3-a]pyrimidine oxazolidinone antibacterial agents. Part II 2011 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Ian A. Cliffe, Om Prakash	8
4	Pharmacodynamic and pharmacokinetic profile of RBx 343E48F0: A novel, long acting muscarinic receptor antagonist 2011 ·European Journal of Pharmacology ·Suman Gupta, Shivani Malhotra, Sandeep Sinha, Shashi Kant Singh, Rakesh Kumar Singh, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jaskiran Kaur, (unknown), Jitendra A. Sattigeri, (unknown), Jyoti Paliwal, Sunanda G. Dastidar, Ian A. Cliffe, Abhijit Ray, Pradip K. Bhatnagar	5
5	Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines 2008 ·Bioorganic & Medicinal Chemistry Letters ·Roger J. Gillespie, Ian A. Cliffe, Claire Dawson, Colin T. Dourish, Suneel Gaur, Allan M. Jordan, Antony R. Knight, Joanne Lerpiniere, Anil Kumar Misra, Robert M. Pratt, (unknown), (unknown), Rebecca Upton, Scott Μ. Weiss, D.S. Williamson	55
6	Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives 2008 ·Bioorganic & Medicinal Chemistry Letters ·Roger J. Gillespie, Ian A. Cliffe, Claire Dawson, Colin T. Dourish, Suneel Gaur, Paul R. Giles, Allan M. Jordan, Antony R. Knight, Anthony J. Lawrence, Joanne Lerpiniere, Anil Kumar Misra, Robert M. Pratt, Richard S. Todd, Rebecca Upton, Scott Μ. Weiss, D.S. Williamson	24
7	Synthesis and optimization of novel and selective muscarinic M3 receptor antagonists 2007 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Kirandeep Kaur, (unknown), (unknown), (unknown), (unknown), Suman Gupta, Anita Chugh, (unknown), Mohammad Salman, Venkata P. Palle, Ian A. Cliffe	4
8	Pyrrolo(iso)quinoline derivatives as 5-HT2C receptor agonists 2005 ·Bioorganic & Medicinal Chemistry Letters ·David R. Adams, Jonathan Bentley, Karen Benwell, (unknown), (unknown), Ian A. Cliffe, Colin T. Dourish, Ashley R. George, G.A. Kennett, Antony R. Knight, (unknown), Howard L. Mansell, Anil Kumar Misra, Kathleen Quirk, (unknown), Steven P. Vickers	20
9	Discovery and development of selective 5-HT2C receptor agonists for obesity 2004 ·Fundamental and Clinical Pharmacology ·Colin T. Dourish, Adams, (unknown), Karen Benwell, Mike Bickerdike, (unknown), G.A. Kennett, A.R. Knight, Sean Lightowler, C Malcolm, Aditya Misra, S P Vickers, Ian A. Cliffe, Philippe Coassolo, Balz Frei, Jacques Mizrahi, Henri Stalder, (unknown)	2
10	A retrospect on the discovery of way-100635 and the prospect for improved 5-HT1A receptor PET radioligands 2000 ·Nuclear Medicine and Biology ·Ian A. Cliffe	38
11	Synthesis, Physicochemical Properties, Anticonvulsant Activities, and GABA-ergic and Voltage-sensitive Calcium Channel Receptor Affinities of α-SubstitutedN-Benzylamides of γ-Hydroxybutyric Acid Part 4: Search for New Anticonvulsant Compounds 1999 ·Archiv der Pharmazie ·Barbara Malawska, Katarzyna Kulig, Lucyna Antkiewicz‐Michaluk, Richard H. Porter, (unknown), Ian A. Cliffe	8
12	Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 1997 ·Brain Research ·Håkan Hall, Camilla Lundkvist, Christer Halldin, Lars Farde, Victor W. Pike, Julie A. McCarron, A Fletcher, Ian A. Cliffe, Tjeerd Barf, Håkan Wikström, Göran Sedvall	240
13	Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11C]WAY-100635 1996 ·European Journal of Pharmacology ·Victor W. Pike, Julie A. McCarron, Adriaan A. Lammertsma, Safiye Osman, Susan P. Hume, Peter A. Sargent, Christopher J. Bench, Ian A. Cliffe, A Fletcher, Paul M. Grasby	178
14	A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635 breakdown → 1995 ·European Journal of Pharmacology ·(unknown), Ian A. Cliffe, David J. Bill, (unknown), Deborah E. Jones, (unknown), Allan Fletcher	550
15	Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist 1995 ·Behavioural Brain Research ·Allan Fletcher, (unknown), David J. Bill, Geraldine Brown, Ian A. Cliffe, (unknown), Deborah E. Jones, (unknown), Kelly J. Stanhope, David Critchley, (unknown), Vicki C. Middlefell, Laurence Lanfumey, Renato Corradetti, Anne‐Marie Laporte, H. Gozlan, Michel Hamon, Colin T. Dourish	473
16	First delineation of 5-HT1A receptors in human brain with PET and [11C]WAY-100635 1995 ·European Journal of Pharmacology ·Victor W. Pike, Julie A. McCarron, (unknown), Susan P. Hume, Keith Poole, Paul M. Grasby, Andrea L. Malizia, Ian A. Cliffe, Allan Fletcher, Christopher J. Bench	85
17	Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain 1994 ·European Journal of Pharmacology ·Susan P. Hume, Sharon Ashworth, Jolanta Opacka‐Juffry, R. G. Ahier, Adriaan A. Lammertsma, Victor W. Pike, Ian A. Cliffe, Allan Fletcher, (unknown)	56
18	Silent 5-HT1A receptor antagonists: utility as research tools and therapeutic agents 1993 ·Trends in Pharmacological Sciences ·Allan Fletcher, Ian A. Cliffe, Colin T. Dourish	177
19	WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors 1993 ·European Journal of Pharmacology ·Allan Fletcher, David J. Bill, (unknown), Ian A. Cliffe, (unknown), (unknown), J. Thomas Haskins, Deborah E. Jones, Howard L. Mansell, (unknown)	198
20	Oral hypoglycemic agents. Pyrimido[1,2-a]indoles and related compounds 1992 ·Journal of Medicinal Chemistry ·Ian A. Cliffe, Eric L. Lien, Howard L. Mansell, Kurt Steiner, Richard S. Todd, (unknown), Robin M. Black	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact